Viking Therapeutics got the market's attention with robust phase 2 results for VK2735, a potential weight loss therapy.
Hosted on MSN1d
Wall Street Analysts Thought Merck Stock Had 10% Downside Risk Heading Into Earnings. That Materialized, So What’s Next?Merck & Co. (NYSE:MRK) is a prominent American multinational pharmaceutical company many investors know for its brand-name ...
It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their U.S.
Shares of Merck & Co. Inc. MRK slid 1.81% to $88.05 Thursday, on what proved to be an all-around mixed trading session for ...
During health secretary nominee Robert F. Kennedy Jr.'s Jan. 29 Senate confirmation hearing, Sen. Elizabeth Warren, D-Mass., ...
With a volume of 12,212,671, the price of MRK is down -1.44% at $88.38. RSI indicators hint that the underlying stock may be ...
Here are seven attractively valued dividend stocks investors can bet on for the long term, according to Bank of America ...
DJIA stocks to watch today. Market trends show gains in retail, tech, and energy. Get insights on Walmart, Apple, Amazon, and more!
NEW YORK, NY / ACCESS Newswire / February 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Merck & ...
Mass General Brigham researchers discovered a previously unknown mechanism that may drive tissue damage and a new target for drug discovery ...
Learn more about whether Biogen Inc. or Gilead Sciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback